Jermaine D Jones1, Mudassir Mumtaz2, Jeanne M Manubay3, Shanthi Mogali3, Elliana Sherwin3, Suky Martinez4, Sandra D Comer3. 1. Division on Substance Use Disorders, New York State Psychiatric Institute and Columbia University Vagelos College of Physicians and Surgeons, 1051 Riverside Drive, New York, NY 10032, USA. Electronic address: Jermaine.Jones@NYSPI.Columbia.edu. 2. Translational Research Training Program in Addiction, City College of New York, 160 Convent Avenue, New York, NY 10031, USA; Sophie Davis School of Biomedical Education, 160 Convent Avenue, New York, NY 10032, USA. 3. Division on Substance Use Disorders, New York State Psychiatric Institute and Columbia University Vagelos College of Physicians and Surgeons, 1051 Riverside Drive, New York, NY 10032, USA. 4. Translational Research Training Program in Addiction, City College of New York, 160 Convent Avenue, New York, NY 10031, USA; Gordon F. Derner School of Psychology, Adelphi University, 1 South Avenue Garden City, NY 11530, USA.
Abstract
BACKGROUND: Attempts to identify opioid users at increased risk of escalating to opioid use disorder have had limited success. Data from a variety of sources suggest that genetic variation may mediate the subjective response to opioid drugs, and therefore contribute to their abuse potential. The goal of the current study was to observe the relationship between select genetic polymorphisms and the subjective effects of oxycodone under controlled clinical laboratory conditions. METHODS: Non-dependent, volunteers with some history of prescription opioid exposure (N = 36) provided a blood sample for analyses of variations in the genes that encode for the μ-, κ- and δ-opioid receptors, and the dopamine metabolizing enzyme, catechol-O-methyltransferase (COMT). Participants then completed a single laboratory test session to evaluate the subjective and analgesic effects of oral oxycodone (0, 10, and 20 mg, cumulative dose = 30 mg). RESULTS: Oxycodone produced typical μ-opioid receptor agonist effects, such as miosis, and decreased pain perception. Oxycodone also produced dose-dependent increases in positive subjective responses such as: drug "Liking" and "Good Effect." Genetic variants in the μ- (rs6848893) and δ-opioid receptor (rs581111) influenced the responses to oxycodone administration. Additionally, self-reported "Stimulated" effects of oxycodone varied significantly as a function of COMT rs4680 genotype. DISCUSSION: The current study shows that the euphoric and stimulating effects of oxycodone can vary as a function of genetic variation. Though the relationship between the stimulating effects of opioids and their abuse liability is not well established, we know that the ability of opioids to provide intense feelings of pleasure is a significant motivator for continued use. If replicated, specific genetic variants may be useful in predicting who is at increased risk of developing maladaptive patterns of use following medical exposure to opioid analgesics.
BACKGROUND: Attempts to identify opioid users at increased risk of escalating to opioid use disorder have had limited success. Data from a variety of sources suggest that genetic variation may mediate the subjective response to opioid drugs, and therefore contribute to their abuse potential. The goal of the current study was to observe the relationship between select genetic polymorphisms and the subjective effects of oxycodone under controlled clinical laboratory conditions. METHODS: Non-dependent, volunteers with some history of prescription opioid exposure (N = 36) provided a blood sample for analyses of variations in the genes that encode for the μ-, κ- and δ-opioid receptors, and the dopamine metabolizing enzyme, catechol-O-methyltransferase (COMT). Participants then completed a single laboratory test session to evaluate the subjective and analgesic effects of oral oxycodone (0, 10, and 20 mg, cumulative dose = 30 mg). RESULTS:Oxycodone produced typical μ-opioid receptor agonist effects, such as miosis, and decreased pain perception. Oxycodone also produced dose-dependent increases in positive subjective responses such as: drug "Liking" and "Good Effect." Genetic variants in the μ- (rs6848893) and δ-opioid receptor (rs581111) influenced the responses to oxycodone administration. Additionally, self-reported "Stimulated" effects of oxycodone varied significantly as a function of COMTrs4680 genotype. DISCUSSION: The current study shows that the euphoric and stimulating effects of oxycodone can vary as a function of genetic variation. Though the relationship between the stimulating effects of opioids and their abuse liability is not well established, we know that the ability of opioids to provide intense feelings of pleasure is a significant motivator for continued use. If replicated, specific genetic variants may be useful in predicting who is at increased risk of developing maladaptive patterns of use following medical exposure to opioid analgesics.
Authors: Elliot C Nelson; Michael T Lynskey; Andrew C Heath; Naomi Wray; Arpana Agrawal; Fiona L Shand; Anjali K Henders; Leanne Wallace; Alexandre A Todorov; Andrew J Schrage; Pamela A F Madden; Louisa Degenhardt; Nicholas G Martin; Grant W Montgomery Journal: Addict Biol Date: 2012-04-13 Impact factor: 4.280
Authors: Sandra D Comer; James P Zacny; Robert H Dworkin; Dennis C Turk; George E Bigelow; Richard W Foltin; Donald R Jasinski; Edward M Sellers; Edgar H Adams; Robert Balster; Laurie B Burke; Igor Cerny; Robert D Colucci; Edward Cone; Penney Cowan; John T Farrar; David J Haddox; Jennifer A Haythornthwaite; Sharon Hertz; Gary W Jay; Chris-Ellyn Johanson; Roderick Junor; Nathaniel P Katz; Michael Klein; Ernest A Kopecky; Deborah B Leiderman; Michael P McDermott; Charles O'Brien; Alec B O'Connor; Pamela P Palmer; Srinivasa N Raja; Bob A Rappaport; Christine Rauschkolb; Michael C Rowbotham; Cristina Sampaio; Beatrice Setnik; Marta Sokolowska; Joseph W Stauffer; Sharon L Walsh Journal: Pain Date: 2012-09-19 Impact factor: 6.961
Authors: K Blum; E R Braverman; J M Holder; J F Lubar; V J Monastra; D Miller; J O Lubar; T J Chen; D E Comings Journal: J Psychoactive Drugs Date: 2000-11
Authors: O Levran; D Londono; K O'Hara; D A Nielsen; E Peles; J Rotrosen; P Casadonte; S Linzy; M Randesi; J Ott; M Adelson; M J Kreek Journal: Genes Brain Behav Date: 2008-06-02 Impact factor: 3.449
Authors: Richard C Crist; James Li; Glenn A Doyle; Alex Gilbert; Bryan M Dechairo; Wade H Berrettini Journal: Am J Drug Alcohol Abuse Date: 2018-01-15 Impact factor: 3.829
Authors: Cherkaouia Kibaly; Jacob A Alderete; Steven H Liu; Hazem S Nasef; Ping-Yee Law; Christopher J Evans; Catherine M Cahill Journal: Cell Mol Neurobiol Date: 2020-11-27 Impact factor: 4.231